公开(公告)号：US10364288B2

公开(公告)日：2019-07-30

申请号：US14890653

申请日：2014-05-23

Applicant: Biogen MA Inc.

Inventor： Joe Salas ,  Siyuan Tan ,  Robert Peters

IPC: A61K39/395 ,  C07K16/28 ,  C12N9/64 ,  C07K14/755

Abstract: The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the α and/or β subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. The invention also includes methods for screening for these antibodies, as well as methods of making and methods of using chimeric molecules derived from the antibodies.

公开(公告)号：US20160115234A1

公开(公告)日：2016-04-28

申请号：US14890653

申请日：2014-05-23

Applicant: BIOGEN MA INC.

Inventor： Joe Salas ,  Siyuan Tan ,  Robert Peters

IPC: C07K16/28 ,  C12N9/64

CPC classification number: C07K16/2848 ,  C07K14/755 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2319/33 ,  C12N9/6408 ,  C12N9/6437 ,  C12Y304/21021

Abstract: The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the α and/or β subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. The invention also includes methods for screening for these antibodies, as well as methods of making and methods of using chimeric molecules derived from the antibodies.

Abstract translation: 本发明提供了特异性结合α和/或bgr的抗体及其抗原结合分子。 GPIIb / IIIa受体的非活性形式的亚单位。 抗体和抗原结合分子可以遗传融合和/或与异源部分缀合，并且用作例如靶向部分。 本发明还包括筛选这些抗体的方法，以及制备方法和使用衍生自抗体的嵌合分子的方法。

公开(公告)号：US20220213200A1

公开(公告)日：2022-07-07

申请号：US17500537

申请日：2021-10-13

Applicant: Biogen MA Inc.

Inventor： Joe Salas ,  Siyuan Tan ,  Robert Peters

IPC: C07K16/28 ,  C07K14/755 ,  C12N9/64

Abstract: The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the α and/or β subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. The invention also includes methods for screening for these antibodies, as well as methods of making and methods of using chimeric molecules derived from the antibodies.